1. A phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer;Alvarez;Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,2002
2. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I/II study;Alvarez;Gynecologic Oncology,1997
3. American Cancer Society. Ovarian cancer statistics | How common is ovarian cancer. (n.d.). Retrieved June 1, 2022, from https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html.
4. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer;Andersson;Anticancer Research,2001
5. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer;Berek;Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,2004